NCT04698837

Brief Summary

Modes of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and specifically the proportion of airborne transmission in this infection is unknown. In the aeroCOVID study, a highly efficient bioaerosol and droplet sampling dummy is used to emulate a susceptible healthcare worker (HCW) and to perform patient proximity sampling. The dummy will measure the dummy-inhaled dose of SARS-CoV-2 in two particle size fractions in a standardized interaction with hospitalized coronavirus disease 2019 (COVID-19) patients. All measurements are performed in a masked and unmasked dummy setup in parallel, in order to gain further information on the protection of type II masks against the respective particle size exposure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 4, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 7, 2021

Completed
26 days until next milestone

Study Start

First participant enrolled

February 2, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

May 18, 2022

Status Verified

May 1, 2022

Enrollment Period

11 months

First QC Date

January 4, 2021

Last Update Submit

May 17, 2022

Conditions

SARS-CoV-2

Keywords

Airborne transmissionAerosol transmissionSurgical masks

Outcome Measures

Primary Outcomes (1)

  • Total amount of dummy-inhaled virus copies per 30 minutes sampling per size fraction (>10 µm, <10 µm)

    30 minutes sampling

Secondary Outcomes (2)

  • Viability of dummy-inhaled viable virus per size fraction (>10 µm, and <10 µm)

    30 minutes sampling

  • Reduction of dummy-inhaled virus copies per 30 minutes sampling in a type II-masked setup, as compared to unmasked, per size fraction (>10 µm, <10 µm)

    30 minutes sampling

Eligibility Criteria

Age18 Years - 110 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study is performed with hospitalized COVID-19 patients at Inselspital, Bern University hospital. The study site hospital is a tertiary university hospital treating COVID-19 patients on normal hospital wards as well as in the intensive care unit.

You may qualify if:

  • positive SARS-CoV-2 PCR or antigen test from a nasopharyngeal or oropharyngeal swab
  • ≥18 years of age
  • ability to give consent
  • ability to follow simple instructions

You may not qualify if:

  • pregnancy
  • lack of written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Bern

Bern, Switzerland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Nasopharyngeal swab

Study Officials

  • Philipp Jent, MD

    University of Bern

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2021

First Posted

January 7, 2021

Study Start

February 2, 2021

Primary Completion

December 31, 2021

Study Completion

December 31, 2021

Last Updated

May 18, 2022

Record last verified: 2022-05

Locations

CH(1)